公开(公告)号：US20240122533A1

公开(公告)日：2024-04-18

申请号：US18546448

申请日：2021-11-15

申请人： OSAKA UNIVERSITY ,  HEARTLAB, INC.

发明人： Shigeru MIYAGAWA ,  Yoshiki SAWA ,  Hidetsugu ASANOI ,  Sunao IKEGAWA

IPC分类号： A61B5/00 ,  A61B5/08

CPC分类号： A61B5/4842 ,  A61B5/0816 ,  A61B5/6892 ,  A61B2562/0247

摘要： The present invention relates to an evaluation device 4 for evaluating the severity of pneumonia in a target patient, comprising: an acquisition unit 42 for acquiring a respiratory waveform of the target patient; a calculation unit 43 for calculating a value of an index indicating instability of a respiratory cycle or a respiratory frequency from the respiratory waveform; and an evaluation unit 44 for evaluating the severity based on the calculated value.

公开(公告)号：US20190153391A1

公开(公告)日：2019-05-23

申请号：US15511275

申请日：2015-09-14

申请人： OSAKA UNIVERSITY

发明人： Yukiko OCHI ,  Kiyotoshi SEKIGUCHI ,  Shigeru MIYAGAWA ,  Yoshiki SAWA ,  Antti Markus SILTANEN

IPC分类号： C12N5/077 ,  C12N5/074 ,  A61K35/34

CPC分类号： C12N5/0657 ,  A61K35/34 ,  C12N5/0696 ,  C12N2506/45 ,  C12N2533/52

摘要： The present invention provides a method for preparing a clinically applicable, safe and less damaged cardiomyocyte population through a brief and simple procedure from a cell population obtained by induced differentiation of pluripotent stem cells into cardiomyocytes. The present invention relates to a method for preparing a cardiomyocyte population, the method comprising the steps of: (1) inducing pluripotent stem cells to differentiate into cardiomyocytes, (2) bringing a cell population obtained by the induced differentiation into contact with a laminin selected from the group consisting of laminin α2β1γ1, laminin α2β2γ1, laminin α1β1γ1 and laminin α1β2γ1, or a fragment thereof having integrin binding activity, and (3) retrieving cells adherent to the laminin or the laminin fragment.

公开(公告)号：US20170304504A1

公开(公告)日：2017-10-26

申请号：US15647742

申请日：2017-07-12

申请人： TERUMO KABUSHIKI KAISHA ,  OSAKA UNIVERSITY

发明人： Fumiya OOHASHI ,  Ryouhei TAKEUCHI ,  Tadashi SAMESHIMA ,  Shigeru MIYAGAWA ,  Yoshiki SAWA ,  Atsuhiro SAITO

IPC分类号： A61L27/58 ,  A61L27/22 ,  A61L27/38 ,  A61L27/52

CPC分类号： A61L27/58 ,  A61L27/225 ,  A61L27/38 ,  A61L27/52 ,  A61L2430/20

摘要： A method for treating a disease associated with tissue abnormality in a subject. The method includes administering an amount of a pharmaceutical composition to a subject in need of treating a disease associated with tissue abnormality, the pharmaceutical composition comprising a laminate comprising a fibrin gel and a cell culture. The laminate is produced by a method, which includes forming a fibrin gel layer on an upper surface of the cell culture by a reaction between fibrinogen and thrombin, wherein: the cell culture is prepared on a culture dish and the laminate of the fibrin gel and the cell culture are transferred onto a subject's heart. The laminate further includes a reinforcing portion made of a fibrin gel, the reinforcing portion formed by laminating the fibrin gel on the fibrin gel layer of the laminate of the cell culture and the fibrin gel.

公开(公告)号：US20240335480A1

公开(公告)日：2024-10-10

申请号：US18579100

申请日：2022-07-14

申请人： Astellas Pharma Inc. ,  OSAKA UNIVERSITY ,  National Center for Child Health and Development

发明人： Kenichiro SHIMATANI ,  Hiromu SATO ,  Masao SASAI ,  Yoshiki SAWA ,  Atsuhiro SAITO ,  Shigeru MIYAGAWA

IPC分类号： A61K35/545 ,  A61K35/44 ,  C12N5/071

CPC分类号： A61K35/545 ,  A61K35/44 ,  C12N5/069 ,  C12N2506/02 ,  C12N2513/00

摘要： An object of the present invention is to provide a pericyte-like cell having high angiogenic potential with a higher cell proliferation ability than a primary pericyte available in the past and high VEGF expression, and a method for producing the same. Provided are a method for producing a VEGF-highly expressing pericyte-like cell, the method including selecting a CD56(−) pericyte-like cell from a population including a pericyte-like cell obtained by inducing differentiation of a pluripotent stem cell; and a VEGF-highly expressing pericyte-like cell produced by the production method.

公开(公告)号：US20180153155A1

公开(公告)日：2018-06-07

申请号：US15872157

申请日：2018-01-16

申请人： TERUMO KABUSHIKI KAISHA ,  OSAKA UNIVERSITY

发明人： Fumiya OHASHI ,  Shigeru MIYAGAWA ,  Yoshiki SAWA ,  Shigeo MASUDA ,  Satsuki FUKUSHIMA ,  Atsuhiro SAITO

IPC分类号： A01N1/02 ,  G01N33/50 ,  C12N5/077 ,  A61K35/545

CPC分类号： A01N1/0215 ,  A01N1/0221 ,  A61K35/28 ,  A61K35/34 ,  A61K35/545 ,  C12N5/0653 ,  C12N5/0657 ,  C12N5/10 ,  G01N33/5073

摘要： A method is disclosed for cryopreservation of cardiocytes derived from pluripotent stem cells or mesenchymal stem cells derived from adipose tissue or bone marrow, the method maintaining the function of the cardiocytes derived from differentiated pluripotent stem cells or mesenchymal stem cells derived from adipose tissue or bone marrow, and yet reducing the possibility for tumorigenesis of undifferentiated pluripotent stem cells or mesenchymal stem cells derived from adipose tissue or bone marrow. A method is also disclosed for cryopreservation of cardiocytes derived from pluripotent stem cells or mesenchymal stem cells (derived from adipose tissue or bone marrow, the method including dissociating cells from a cell population which has been induced to differentiate into cardiocytes from pluripotent stem cells or mesenchymal stem cells derived from adipose tissue or bone marrow.

公开(公告)号：US20240197753A1

公开(公告)日：2024-06-20

申请号：US18283585

申请日：2022-03-25

申请人： OSAKA UNIVERSITY ,  CUORIPS INC.

发明人： Yoshiki SAWA ,  Shigeru MIYAGAWA ,  Yoshiki SAKAI ,  Yasuhiro YANAGI

IPC分类号： A61K31/559 ,  A61K9/06 ,  A61K9/16 ,  A61K9/70 ,  A61K47/42 ,  A61P9/04

CPC分类号： A61K31/559 ,  A61K9/06 ,  A61K9/1647 ,  A61K9/7007 ,  A61K47/42 ,  A61P9/04

摘要： An object is to provide a pharmaceutical composition that improves cardiac function when administered during coronary artery bypass surgery for ischemic cardiomyopathy. A pharmaceutical composition for improving cardiac function comprising: (A) a release formulation comprising at least poly(lactic-co-glycolic acid) (PLGA) and a prostaglandin 12 receptor agonist, the PLGA having an average molecular weight of 10000 to 30000; and (B) a release formulation comprising at least poly(lactic-co-glycolic acid) (PLGA) and a prostaglandin 12 receptor agonist, the PLGA having an average molecular weight of 40000 to 60000.

公开(公告)号：US20230157634A1

公开(公告)日：2023-05-25

申请号：US17920398

申请日：2021-04-22

申请人： OSAKA UNIVERSITY

发明人： Hidetsugu ASANOI ,  Yoshiki SAWA ,  Shigeru MIYAGAWA ,  Sunao IKEGAWA

IPC分类号： A61B5/00 ,  A61B5/11

CPC分类号： A61B5/4842 ,  A61B5/7267 ,  A61B5/7275 ,  A61B5/7246 ,  A61B5/1115 ,  A61B5/6892 ,  A61B2562/0247

摘要： This invention relates to a prediction support system and associated methods for supporting prediction of the severity of a disease. The systems and methods may perform operations that include continuously detecting whether a patient with the disease is in bed, and acquiring, based on the detection result of the detecting, an in-bed pattern indicating, as a time series, whether the patient is in bed. The systems may include a detection device and an acquisition unit.

公开(公告)号：US20220142507A1

公开(公告)日：2022-05-12

申请号：US17585199

申请日：2022-01-26

申请人： Sumitomo Riko Company Limited ,  Osaka University

发明人： Wataru TAKAHASHI ,  Masanori YAMAMOTO ,  Atsuki SHIMIZU ,  Mitsuyoshi KONDO ,  Jun Taguchi ,  Hidetsugu ASANOI ,  Yoshiki SAWA ,  Shigeru MIYAGAWA

IPC分类号： A61B5/113 ,  A61B5/00 ,  A61B5/11

摘要： A heart failure diagnostic device includes a piezoelectric sensor sheet having flexibility and configured to output a detection signal corresponding to an input vibration. A respiratory signal acquisition unit is configured to extract, as a respiratory signal, a signal of a vibration frequency caused by respiration from the detection signal detected by the piezoelectric sensor sheet. A power spectrum calculator is configured to obtain a power spectrum of a respiratory frequency band from the respiratory signal, and a signal corrector is configured to correct the detection signal such that in the power spectrum, a maximum value of a first-order frequency component of a respiratory waveform is not smaller than 1.5 times a maximum value of a second-order frequency component of the respiratory waveform to obtain the respiratory signal.

公开(公告)号：US20180042220A1

公开(公告)日：2018-02-15

申请号：US15784460

申请日：2017-10-16

申请人： TERUMO KABUSHIKI KAISHA ,  Osaka University

发明人： Shigeru MIYAGAWA ,  Yoshiki Sawa ,  Hirotatsu Ohkawara ,  Satsuki Fukushima ,  Atsuhiro Saito ,  Hiroko Iseoka

IPC分类号： A01N1/02

CPC分类号： A01N1/0268 ,  A01N1/021 ,  C12N1/04

摘要： Methods are disclosed of freezing, cryopreserving, and transferring a frozen sheet-shaped cell culture. The method of freezing includes (1) a step of immersing in a cryopreservation solution a sheet-shaped cell culture supported by a mesh-shaped support body; (2) a step of removing the cryopreservation solution adhered to the sheet-shaped cell culture, while keeping the sheet-shaped cell culture supported by the mesh-shaped support body; (3) a step of enclosing the sheet-shaped cell culture in a cold-resistant film, an upper surface and a lower surface of the sheet-shaped cell culture being covered by the mesh-shaped support body; and (4) a step of freezing the sheet-shaped cell culture.

公开(公告)号：US20240358765A1

公开(公告)日：2024-10-31

申请号：US18767576

申请日：2024-07-09

申请人： Terumo Kabushiki Kaisha ,  Osaka University

发明人： Hidetoshi EGUCHI ,  Yoshito TOMIMARU ,  Shigeru MIYAGAWA ,  Keisuke TOYA ,  Fumiya OHASHI

IPC分类号： A61K35/34 ,  A61P1/16 ,  C12N5/077

CPC分类号： A61K35/34 ,  A61P1/16 ,  C12N5/0658 ,  C12N2502/28

摘要： A composition comprising skeletal myoblasts for treating liver dysfunction or improving liver function, in which the liver dysfunction can be hepatitis, liver fibrosis, liver cirrhosis, liver cancer, or liver failure. The composition can be used for promoting the proliferation of liver cells, regeneration of the liver tissue and/or angiogenesis, and providing a method for treating liver dysfunction, including a step of treating applying the composition to a site exhibiting liver dysfunction.